Catalyst
A recent MACD Death Cross signal indicates a bullish bias for ELAN.
The analyst consensus includes a single Buy rating, reflecting initial institutional optimism.
Risk
Fund flows show negative trends across all size buckets indicating outflows and reduced investor interest.
Market expectations for ELAN are pessimistic with analyst ratings showing differences in views.
News surrounding U.S. pharmaceutical pricing policies and regulatory changes could introduce volatility and uncertainty for ELAN.
Generated at21:3002/06/2026by
Aime